Read clinical review Clinical Reviews GHK-Cu + Epitalon Stack: Evidence, Mechanism Overlap, and Protocol A detailed clinical review of stacking GHK-Cu (copper tripeptide) with Epitalon (tetrapeptide), covering mechanism overlap, evidence quality, dosing protocols, and safety considerations
This manuscript provides a comprehensive summary of the clinical pharmacology of GLP-1RAs and GLP-1/GIP dual receptor agonists, with particular emphasis on tirzepatide
Pramlintide was the first-generation amylin analog with a short half-life (~50 minutes), requiring multiple daily administrations
Disulfide bridge formation is reversible
Holding at a dose for an extra 4 weeks before escalating is a medically supported strategy when: Nausea or vomiting persists beyond 2 weeks at the current dose You are unable to eat at least 1,000 calories per day comfortably Dehydration symptoms appear (dark urine, dizziness on standing, dry mouth) You are losing weight faster than 1 to 2 pounds per week on the current dose (aggressive weight loss increases side effect risk) In the STEP trials, delayed escalation did not compromise overall weight loss outcomes at 68 weeks
In any patient on a bisphosphonate who reports new-onset hip or thigh pain without a clear traumatic mechanism, this should be communicated to the medical team promptly